SCHEMBL580662

SCHEMBL580662

Clc1ncccc1-c1cnn(C(c2ccccc2)(c2ccccc2)c2ccccc2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.39
MAPT P10636 2/20 0.39
RAB9A P51151 2/20 0.39
PKM P14618 1/20 0.39
KCNN4 O15554 1/20 0.37
KCNA3 P22001 1/20 0.37
KDM4E B2RXH2 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
DHODH Q02127 3/20 0.35
GRM4 Q14833 4/20 0.33
NPSR1 Q6W5P4 2/20 0.33
AURKA O14965 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
RECQL P46063 1/20 0.33
PDK2 Q15119 2/20 0.33
KDR P35968 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL510894 0.83 MAP4K4 (0.41) KCNN4KCNA3KDM4EGRM4PDK2
SCHEMBL19078741 0.77 GRM4 (0.41) NPC1RAB9ASMN1; SMN2GRM4ALDH1A1
SCHEMBL70574 0.75 L3MBTL1 (0.44) NPC1RAB9AKCNN4KCNA3SMN1; SMN2
SCHEMBL17276686 0.74 TRPA1 (0.43) KCNN4KCNA3CYP1A2CYP2C19PDK2
SCHEMBL27869499 0.74 L3MBTL1 (0.52) NPC1MAPTRAB9AKDM4ECYP1A2
SCHEMBL4784136 0.73 L3MBTL1 (0.60) KDM4ECYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL18229954 0.72 KCNN4 (0.42) MAPTRAB9AKCNN4KCNA3CYP1A2
SCHEMBL19032085 0.71 SMN1; SMN2 (0.42) NPC1MAPTRAB9APKMKDM4E
SCHEMBL3826876 0.71 KCNN4 (0.33) NPC1RAB9AKCNN4KCNA3CYP1A2
SCHEMBL3327536 0.71 DHODH (0.50) NPC1MAPTRAB9APKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242961-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2016-01-26 US disclosed
EP-1984353-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2015-12-30 EP disclosed
EP-2418209-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-06-25 EP disclosed
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2014-03-06 US disclosed
EP-2418209-A1 Aurora kinase modulators and method of use Amgen Inc. (US) 2012-02-15 EP disclosed
US-20110263530-A1 Aurora Kinase Modulators and Method of Use AMGEN INC. (US) 2011-10-27 US disclosed
US-8022221-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2011-09-20 US disclosed
US-7560551-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-07-14 US disclosed
US-20090163501-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-06-25 US disclosed
CN-101405282-A Aurora kinase modulators and methods of use AMGEN INC (US) 2009-04-08 CN disclosed
EP-1984353-A1 AURORA KINASE MODULATORS AND METHOD OF USE Amgen, Inc (US) 2008-10-29 EP disclosed
US-20070185111-A1 Aurora kinase modulators and method of use AMGEN INC. 2007-08-09 US disclosed
WO-2007087276-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, AURKB NPC1 1051/4885MAPT 2283/4885RAB9A 1770/4885
US-20070185111-A1 Aurora kinase modulators and method of use AURKC, AURKA, CDK1 NPC1 996/4885MAPT 1958/4885RAB9A 2470/4885
US-20110263530-A1 Aurora Kinase Modulators and Method of Use AURKC, AURKA, AURKB NPC1 1051/4885MAPT 2283/4885RAB9A 1770/4885
US-20090163501-A1 Aurora kinase modulators and method of use AURKC, AURKA, AURKB NPC1 1051/4885MAPT 2283/4885RAB9A 1770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.